Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer
Cho SH et al. - In a trial to evaluate the efficacy and safety of concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer, it was shown that the main hematological toxicity was neutropenia, but no neutropenic fever was observed. The major non-hematological toxicities were asthenia and vomiting, mostly of grades 1 and 2. Concurrent chemoradiotherapy with S-1 and cisplatin may be a promising nonsurgical treatment in advanced esophageal cancer Methods- Pts with locally advanced or metastatic squamous cell carcinoma of the esophagus received S-1 and cisplatin at doses of 70 mg/m2/day for 14 days and 70 mg/m2 on day 1, respectively, every 3 weeks
- Concurrently, radiotherapy was started at a dose of 200 cGy/day, up to a total of 5400 cGy
- After concurrent chemoradiotherapy, additive chemotherapy was repeated up to 6 cycles
Results- 30 pts were enrolled; of the 27 in whom efficacy could be evaluated, an objective response rate was seen in 20, including 5 complete pathologic responses in primary lesions
- Improvement of dysphagia was seen in 21 pts
- In pts with stage II or III esophageal cancer, median progression-free survival and overall survival were 10.6 months, respectively
- In pts with stage IV esophageal cancer, median progression-free survival and overall survival were 5.4 months and 11.6 months, respectively
[more...]
|
|
|
